NCT00479648View on ClinicalTrials.gov

A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

612

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

CSL412

BIOLOGICAL

Inactivated trivalent influenza vaccine

Trial Locations (1)

Unknown

Chiltern International, Slough

All Listed Sponsors
lead

Seqirus

INDUSTRY

NCT00479648 - A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants | Biotech Hunter | Biotech Hunter